B+
Bull case
25%
Probability
Target price
$9.00
Analysis reference price unavailable
Analysis 2026-09-12 · RankAlpha Sentiment Codex
AARD
Aardvark TherapeuticsDNasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
Quote time unavailable
AI scenario view
RankAlpha Sentiment CodexMost likely
B
Base case
40%
Probability
Target price
$4.50
Analysis reference price unavailable
Analysis 2026-09-12 · RankAlpha Sentiment Codex
B-
Bear case
35%
Probability
Target price
$2.50
Analysis reference price unavailable
Analysis 2026-09-12 · RankAlpha Sentiment Codex
The current persistence contract does not provide an exact AI reference price. RankAlpha therefore does not calculate scenario return from the live quote. How scenarios are presented
AI sentiment snapshot
Latest data as of 2026-09-12
Recent news sentiment (30D)
-0.7
Mixed
Company
-
Unavailable
Macro
-
Unavailable
Pulse
-
Unavailable
Weekly research (10D)
-
Unavailable
Sentiment proxy
+49.3
Score
AI commentary
Primary-source tone remains negative because the lead program is on full clinical hold and its Phase 3 trials were terminated, partly offset by runway into late 2027. Recent coverage is sparse and includes investor-law-firm solicitation and a procedural annual-meeting recap rather than substantive new clinical evidence. No reliable social, options-skew, short-interest, employee-review, post-event analyst-revision, or attributable market-reaction data is available; the zero placeholders in the sentiment object mean unavailable, not neutral. The deterministic prior is negative, and the memo remains a low-coverage monitoring view.
RankAlpha Sentiment Codex - 2026-09-12
Open full AI memoEvidence flagged
No evidence quality warning is currently attached to this memo.
Impact
standard
Confidence
-
AI events
2026-09-30eventHERO/OLE data assessment and ARD-101 decisionHigh impact
Management said it was assessing unblinded Phase 3 HERO and open-label-extension efficacy and safety data during the third quarter of 2026 to determine next steps. A favorable interpretation could preserve development value, but the trials were terminated and are not expected to resume as previously designed. [#SEC-8K-2026-08-11]
2026-12-31eventFDA engagement may clarify whether ARD-101 can advanceHigh impact
Aardvark reported active discussions with the FDA about resolving the clinical hold, but disclosed no restart criteria, timetable, or assured outcome. Any concrete resolution would be consequential; continued uncertainty would reinforce the monitoring stance. [#SEC-8K-2026-08-11]
2026-12-31catalystClinical hold remains the central downside riskHigh impact
The FDA full clinical hold covers ARD-101 studies, including HERO and the Phase 3 OLE trial. Failure to identify a viable regulatory and development path could drive further program impairment. [#SEC-8K-2026-08-11]
Recommendation
N/A
No formal recommendation provided.
As of 2026-09-12 • Updated nightlySource: Internal modelMethodology